Prognostic Role of Examined and Positive Lymph Nodes after Distal Pancreatectomy for Non-Functioning Neuroendocrine Neoplasms.


Journal

Neuroendocrinology
ISSN: 1423-0194
Titre abrégé: Neuroendocrinology
Pays: Switzerland
ID NLM: 0035665

Informations de publication

Date de publication:
2021
Historique:
received: 10 04 2020
accepted: 23 06 2020
pubmed: 26 6 2020
medline: 27 1 2022
entrez: 26 6 2020
Statut: ppublish

Résumé

The most appropriate nodal staging system for non-functioning pancreatic neuroendocrine tumours (NF-PanNETs) remains unclear. Despite some evidence is available for pancreaticoduodenectomy, the adequate nodal staging is still unknown for distal pancreatectomy (DP). The aim of the present study was to evaluate the prognostic impact of the number of positive lymph nodes (PLNs) after DP for NF-PanNETs and to define the minimal number of lymph nodes to be harvested for an appropriate nodal staging. Data were retrospectively collected from patients who underwent DP with curative intent (R0-R1) for sporadic well-differentiated NF-PanNETs in 4 European high-volume centres. NF-PanNETs with nodal involvement (N+) were subclassified into N1 (1-3 PLNs) and N2 (4 or more PLNs). Univariate and multivariate analyses of disease-free survival (DFS) were performed. Of 271 patients in the study, 62 (23%) had nodal involvement (N+). A higher probability of N+ was associated with the following factors: grading, resection margin status, perineural and microvascular invasion, and the number of examined lymph nodes. Three-year DFS rate for N0, N1, and N2 patients was 92, 72, and 50%, respectively (p < 0.001). At multivariate analysis, independent predictors of DFS were grading, T stage, presence of necrosis, and nodal status. For patients with ≥12 examined/resected lymph nodes, the N status remained a significant predictor of disease recurrence (p < 0.001), while it failed to predict recurrence in patients with <12 lymph nodes examined/resected (p = 0.116). A minimal number of 12 nodes should be harvested in case of DP for NF-PanNET for an appropriate nodal staging. The number of positive lymph nodes is an independent predictor of DFS after DP for NF-PanNET, and the N0/N1/N2 nodal classification seems to be more relevant than the current N0/N+ staging.

Sections du résumé

BACKGROUND
The most appropriate nodal staging system for non-functioning pancreatic neuroendocrine tumours (NF-PanNETs) remains unclear. Despite some evidence is available for pancreaticoduodenectomy, the adequate nodal staging is still unknown for distal pancreatectomy (DP). The aim of the present study was to evaluate the prognostic impact of the number of positive lymph nodes (PLNs) after DP for NF-PanNETs and to define the minimal number of lymph nodes to be harvested for an appropriate nodal staging.
METHODS
Data were retrospectively collected from patients who underwent DP with curative intent (R0-R1) for sporadic well-differentiated NF-PanNETs in 4 European high-volume centres. NF-PanNETs with nodal involvement (N+) were subclassified into N1 (1-3 PLNs) and N2 (4 or more PLNs). Univariate and multivariate analyses of disease-free survival (DFS) were performed.
RESULTS
Of 271 patients in the study, 62 (23%) had nodal involvement (N+). A higher probability of N+ was associated with the following factors: grading, resection margin status, perineural and microvascular invasion, and the number of examined lymph nodes. Three-year DFS rate for N0, N1, and N2 patients was 92, 72, and 50%, respectively (p < 0.001). At multivariate analysis, independent predictors of DFS were grading, T stage, presence of necrosis, and nodal status. For patients with ≥12 examined/resected lymph nodes, the N status remained a significant predictor of disease recurrence (p < 0.001), while it failed to predict recurrence in patients with <12 lymph nodes examined/resected (p = 0.116).
CONCLUSIONS
A minimal number of 12 nodes should be harvested in case of DP for NF-PanNET for an appropriate nodal staging. The number of positive lymph nodes is an independent predictor of DFS after DP for NF-PanNET, and the N0/N1/N2 nodal classification seems to be more relevant than the current N0/N+ staging.

Identifiants

pubmed: 32585667
pii: 000509709
doi: 10.1159/000509709
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

728-738

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Giovanni Guarneri (G)

Department of Hepato-Bilio-Pancreatic Surgery, ENETS Centre of Excellence, Beaujon Hospital, APHP, Clichy, France, guarneri.giovanni@hsr.it.
Pancreatic Surgery Unit, ENETS Centre of Excellence, Pancreas Translational and Clinical Research Centre, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, guarneri.giovanni@hsr.it.

Louis de Mestier (L)

Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon Hospital, APHP, Clichy, France.

Luca Landoni (L)

General and Pancreatic Surgery, Pancreas Institute, University of Verona, Verona, Italy.

Stefano Partelli (S)

Pancreatic Surgery Unit, ENETS Centre of Excellence, Pancreas Translational and Clinical Research Centre, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Sébastien Gaujoux (S)

Department of Digestive and Endocrine Surgery, Cochin Hospital, APHP, Paris, France.

Valentina Andreasi (V)

Pancreatic Surgery Unit, ENETS Centre of Excellence, Pancreas Translational and Clinical Research Centre, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Chiara Nessi (C)

General and Pancreatic Surgery, Pancreas Institute, University of Verona, Verona, Italy.

Safi Dokmak (S)

Department of Hepato-Bilio-Pancreatic Surgery, ENETS Centre of Excellence, Beaujon Hospital, APHP, Clichy, France.

Michele Fontana (M)

General and Pancreatic Surgery, Pancreas Institute, University of Verona, Verona, Italy.

Bertrand Dousset (B)

Department of Digestive and Endocrine Surgery, Cochin Hospital, APHP, Paris, France.

Philippe Ruszniewski (P)

Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon Hospital, APHP, Clichy, France.

Claudio Bassi (C)

General and Pancreatic Surgery, Pancreas Institute, University of Verona, Verona, Italy.

Massimo Falconi (M)

Pancreatic Surgery Unit, ENETS Centre of Excellence, Pancreas Translational and Clinical Research Centre, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Alain Sauvanet (A)

Department of Hepato-Bilio-Pancreatic Surgery, ENETS Centre of Excellence, Beaujon Hospital, APHP, Clichy, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH